Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma

Pharmacology, Toxicology and Pharmaceutical Science

• Bendamustine 100%
• Chronic Lymphatic Leukemia 100%
• Nonhodgkin Lymphoma 100%
• Rituximab 100%
• Benzimidazole 17%
• Chlorambucil 17%
• Multiple Myeloma 17%
• Chlormethine Derivative 13%
• Clinical Study 8%
• Toxicity 8%
• Drug 8%
• Adverse Event 8%
• Progression Free Survival 8%
• Purine 8%
• Nitrogen Mustard 4%
• Pharmacodynamics 4%
• Alkylating Agent 4%
• Purine Derivative 4%
• Hodgkin Disease 4%
• CYP1A2 4%
• Breast Cancer 4%
• Infection 4%
• Hematologic Malignancy 4%
• Remission 4%
• Fatigue 4%
• Amino Acid 4%
• Nausea 4%
• Active Metabolite 4%
• Fever 4%
• Disease 4%
• Monotherapy 4%
• Bioavailability 4%
• First Pass Effect 4%
• Cross-Resistance 4%
• Xerostomia 4%
• Isoprenaline 4%